Retraction: 3,30-diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer(Cancer Res (2009)69 (5592–600) DOI: 10.1158/0008-5472.CAN-09-0838);3,3′-diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer

Cancer Research

Volumn 69, Issue 13, 2009, Pages 5592-5600

  Banerjee, Sanjeev ^a   Wang, Zhiwei ^a   Kong, Dejuan ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIINDOLYLMETHANE; CASPASE 3; CISPLATIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXALIPLATIN; PROTEIN BCL XL; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; CYTOCHROME C; DEOXYCYTIDINE; DIINDOLYLMETHANE; DRUG DERIVATIVE; INDOLE DERIVATIVE; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR VOLUME; WESTERN BLOTTING; CELL SURVIVAL; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CYTOCHROMES C; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; INDOLES; NF-KAPPA B; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS;

EID: 67650496175     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-1176     Document Type: Erratum

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Lage H, Dietel M. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 2002;128:349-57.
3. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
4. Hu X, Xuan Y. Bypassing cancer drug resistance by activating multiple death pathways - a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett 2008;259:127-37.
5. Arlt A, Schafer H. NFκB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 2002;40:336-47.
6. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
7. Grose KR, Bjeldanes LF. Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol 1992;5:188-93.
8. Keck AS, Finley JW. Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Integr Cancer Ther 2004;3:5-12.
9. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005;4:1201-15.
10. Reed GA, Arneson DW, Putnam WC, et al. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3′-diindolylmethane. Cancer Epidemiol Biomarkers Prev 2006;15:2477-81.
11. Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, Sarkar FH. Apoptosis-inducing effect of erlotinib is potentiated by 3,3′- diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 2008;7:1708-19.
12. Chinnakannu K, Chen D, Li Y, et al. Cell cycle-dependent effects of 3,3′-diindolylmethane on proliferation and apoptosis of prostate cancer cells. J Cell Physiol 2009;219:94-9.
13. Bhuiyan MM, Li Y, Banerjee S, et al. Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006;66:10064-72.
14. Kong D, Banerjee S, Huang W, et al. Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 2008;68:1927-34.
15. Li Y, Chinni SR, Sarkar FH. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-κB pathways in prostate cancer cells. Front Biosci 2005;10:236-43.
16. Nachshon-Kedmi M, Fares FA, Yannai S. Therapeutic activity of 3,3′-diindolylmethane on prostate cancer in an in vivo model. Prostate 2004;61:153-60.
17. Rahman KW, Sarkar FH. Inhibition of nuclear translocation of nuclear factor-κB contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 2005;65:364-71.
18. Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S. 3,3′-Diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006;27:717-28.
19. Carter TH, Liu K, Ralph W, Jr., et al. Diindolylmethane alters gene expression in human keratinocytes in vitro . J Nutr 2002;132:3314-24.
20. Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH. Chemoprevention of pancreatic cancer: characterization of Par-4 andits modulation by 3,3′ diindolylmethane (DIM). Pharm Res 2008;25:2117-24.
21. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis andinvasio n by 3,3′-diindolylmethane is mediated by the nuclear factor-κB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007;67:3310-9.
22. Li Y, Wang Z, Kong D, et al. Regulation of FOXO3a/β-catenin/GSK- 3β signaling by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 2007;282:21542-50.
23. Chang X, Firestone GL, Bjeldanes LF. Inhibition of growth factor-induced Ras signaling in vascular endothelial cells andangiogenesis by 3,3′-diindolylmethane. Carcinogenesis 2006;27:541-50.
24. Rahman KM, Ali S, Aboukameel A, et al. Inactivation of NF-κB by 3,3′-diindolylmethane contributes to increasedapopto sis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007;6:2757-65.
25. Reed GA, Sunega JM, Sullivan DK, et al. Single-dose pharmacokinetics andtoler ability of absorptionenhanced3,3 ¶-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008;17:2619-24.
26. Crowell JA, Page JG, Levine BS, Tomlinson MJ, Hebert CD. Indole-3-carbinol, but not its major digestive product 3,3′- diindolylmethane, induces reversible hepatocyte hypertrophy andcyt ochromes P450. Toxicol Appl Pharmacol 2006;211:115-23.
27. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 2006;66:3347-50.
28. Ducreux M, Boige V, Malka D. Treatment of advanced pancreatic cancer. Semin Oncol 2007;34:S25-30.
29. O'Reilly EM, bou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007;34:347-53.
30. Xiong HQ, Carr K, Abbruzzese JL. Cytotoxic chemotherapy for pancreatic cancer: advances to date and future directions. Drugs 2006;66:1059-72.
31. Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother 2007;8:2719-27.
32. Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005;65:9064-72.
33. Banerjee S, Zhang Y, Wang Z, et al. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 2007;120:906-17.
34. Lee MA, Park GS, Lee HJ, et al. Survivin expression andits clinical significance in pancreatic cancer. BMC Cancer 2005;5:127.
35. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers andmyeloid leukemias. Clin Cancer Res 2000;6:1796-803.
36. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int J Cancer 2003;105:735-46.
37. Holcomb B, Yip-Schneider M, Schmidt CM. The role of nuclear factor κB in pancreatic cancer andthe clinical applications of targeted therapy. Pancreas 2008;36:225-35.
38. Pan X, Arumugam T, Yamamoto T, et al. Nuclear factor-κB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 2008;14:8143-51.
39. Chuang SE, Yeh PY, Lu YS, et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), andit s attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 2002;63:1709-16.
40. Zhang Y, Gavriil M, Lucas J, et al. IκBα kinase inhibitor IKI-1 conferredtu mor necrosis factor a sensitivity to pancreatic cancer cells anda xenograft tumor model. Cancer Res 2008;68:9519-24.
41. Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. Oncogene 2003;22:1365-70.
42. Martinez-Cardus A, Martinez-Balibrea E, Bandres E, et al. Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Mol Cancer Ther 2009;8:194-202.
43. Lee JU, Hosotani R, Wada M, et al. Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer 1999;35:1374-80.
44. Sharma J, Srinivasan R, Majumdar S, Mir S, Radotra BD, Wig JD. Bcl-XL protein levels determine apoptotic index in pancreatic carcinoma. Pancreas 2005;30:337-42.
45. Bai J, Sui J, Demirjian A, Vollmer CM, Jr., Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related-apoptosis-ind ucing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro . Cancer Res 2005;65:2344-52.
46. Ferrandina G, Legge F, Martinelli E, et al. Survivin expression in ovarian cancer andits correlation with clinico-pathological, surgical andapoptosi s-related parameters. Br J Cancer 2005;92:271-7.
47. Takai N, Ueda T, Nishida M, Nasu K, Miyakawa I. The relationship between oncogene expression andclinical outcome in endometrial carcinoma. Curr Cancer Drug Targets 2004;4:511-20.
48. Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005;247:35-88.
49. Liu WS, Yan HJ, Qin RY, et al. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci 2009;54:89-96.